17191-44-5

Basic information

• Product Name: CBZ-1-AMINO-1-CYCLOPENTANECARBOXYLIC ACID
• Synonyms: CBZ-1-AMINO-1-CYCLOPENTANECARBOXYLIC ACID;Z-CLE-OH;Z-NH(1)CPEN-OH;N-ALPHA-CARBOBENZOXY-1-AMINOCYCLOPENTANECARBOXYLIC ACID;N-ALPHA-CARBOBENZOXY-CYCLOLEUCINE;RARECHEM AL CF 0201;Cyclopentanecarboxylic acid, 1-[[(phenylmethoxy)carbonyl]amino]- (9CI);Cbz-Cyclolencine
• CAS NO: 17191-44-5
• Molecular Formula: C₁₄H₁₇NO₄
• Molecular Weight: 263.29
• Product Categories: N-CBZ;pharmacetical
• Mol File: 17191-44-5.mol

Chemical Properties

• Boiling Point: 468.239 °C at 760 mmHg
• Flash Point: 236.983 °C
• Appearance: /
• Density: 1.263 g/cm³
• Vapor Pressure: 1.43E-09mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: CBZ-1-AMINO-1-CYCLOPENTANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: CBZ-1-AMINO-1-CYCLOPENTANECARBOXYLIC ACID(17191-44-5)
• EPA Substance Registry System: CBZ-1-AMINO-1-CYCLOPENTANECARBOXYLIC ACID(17191-44-5)

Safety Data

• Hazardous Substances Data: 17191-44-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CBZ-1-AMINO-1-CYCLOPENTANECARBOXYLIC ACID is used as a key intermediate for the synthesis of various drugs and pharmaceuticals. Its unique structure and reactivity make it a valuable building block in the development of new medicinal compounds, contributing to the advancement of treatments for a range of diseases and conditions.
Used in Organic Chemistry Synthesis:
In the realm of organic chemistry, CBZ-1-AMINO-1-CYCLOPENTANECARBOXYLIC ACID is utilized as a fundamental component in the synthesis of complex organic molecules. Its versatility in chemical reactions allows for the creation of a wide array of organic compounds, further expanding the scope of chemical research and application.

InChI:InChI=1/C14H17NO4/c16-12(17)14(8-4-5-9-14)15-13(18)19-10-11-6-2-1-3-7-11/h1-3,6-7H,4-5,8-10H2,(H,15,18)(H,16,17)

Upstream product

• 501-53-1 benzyl chloroformate 
• 52-52-8 1-amino-1-cyclopentanecarboxylic acid 

Downstream Products

• 101813-77-8 N-[[1-[[(phenylmethoxy)carbonyl]amino]-1-cyclopentyl]carbonyl]-L-tyrosine ethyl ester 
• 17191-51-4 1-(Benzyloxycarbonylamino)-cyclopentan-1-carbonsaeureamid 
• 94999-60-7 1-(1-Benzyloxycarbonylamino-cyclopentylcarbonylamino)-cyclopentan-carbonsaeure-⁽¹⁾-methylester 
• 940868-36-0 benzyl {1-[amino(hydroxyimino)methyl]cyclopentyl}carbamate 
• 519032-32-7 2-(1-amino-cyclopentyl)-5,6-dihydroxy-pyrimidine-4-carboxylic acid 4-fluoro-benzylamide 
• 519032-31-6 {1-[4-(4-fluoro-benzylcarbamoyl)-5,6-dihydroxy-pyrimidin-2-yl]-cyclopentyl}-carbamic acid benzyl ester 
• 14855-33-5 6,13-diaza-dispiro[4.2.4.2]tetradecane-7,14-dione 
• 17193-28-1 1-aminocyclopentane-1-carboxamide 
• 17193-46-3 1-(N-Benzyloxycarbonyl-β-O-benzyl-asparagyl-amino)-cyclopentan-1-carbonsaeureamid 

Relevant articles and documents

BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME

Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well a

NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS

Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Diso

ENZYME AND RECEPTOR MODULATION

Covalent conjugates of an α,α-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the α,α-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells.

INHIBITORS OF P38 MAP KINASE

Compounds of formula (I) are p38 MAP kinase inhibitors useful for the treatment of autoimmune and inflammatory diseases: wherein: G is -N= or -CH=; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5 - 13 ring members; R6 is hydrogen or optionally substituted CrC3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula (IA); wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members; z is O or 1; -X1-L1-Y- is a linker radical or bond; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; and R2 and R3 are as defined in the claims.

CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS

Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such condit

Synthesis and pharmacological evaluation of glycine-modified analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid (GPE)

The synthesis of 10 G*PE analogues, wherein the glycine residue has been modified, is described by coupling readily accessible dibenzyl-l-prolyl-l- glutamate 2 with various analogues of glycine. Pharmacological evaluation of the novel compounds was undertaken to further understand the role of the glycine residue on the observed neuroprotective properties of the endogenous tripeptide GPE.

NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE

Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and

Zinc promoted rapid and efficient synthesis of Fmoc- and Z-α,α-dialkylamino acids under neutral conditions

The introduction of Nα-9-fluorenylmethyloxycarbonyl (Fmoc) and benzyloxycarbonyl (Z) groups into α,α-dialkylamino acids is described at neutral pH using Fmoc-Cl or Z-Cl as an acylating agent respectively in the presence of activated zing powder. The reaction is simple, fast and clean. It also permits the scale up with high yields. It is completely free from protected oligomer formation, which is a known side-reaction when Schotten-Baumann procedure is followed. All the Fmoc- and Z-amino acids prepared have been fully characterized.

Efficient large scale preparation of neutral endopeptidase/ angiotensin-converting enzyme dual inhibitor CGS30440

The development and piloting of a potential manufacturing process for ACE/NEP dual inhibitor CGS30440 is described. The synthesis proceeds sequentially from 1-aminocyclopentanecarboxylic acid via N-protection, peptide coupling with L-tyrosine ethyl ester, O-methylation of N-protected [(1-amino-1-cyclopentyl)carbonyl]-L-tyrosine ethyl ester, N-deprotection, peptide coupling of [(1-amino-1-cyclopentyl)carbonyl]-O-methyl-L-tyrosine ethyl ester with D-2-bromo-3-methylbutyric acid, and final displacement of bromide with thioacetate. This approach is superior to shorter Discovery routes based upon final peptide coupling of L-2-(acetylthio)-3-methylbutanoic acid to [(1-amino-1-cyclopentyl)carbonyl]-O-methyl-L-tyrosine ethyl ester.